CXCL8 can recruit neutrophils and MDSC around cancer cells to form neutrophil extracellular traps (NETs) and protect them from cytotoxicity mediated by CD8+ T cells and natural kill (NK) cells, which in turn affects the efficacy of ICIs therapy [25]. Here, CXCL8 is linked to cancer.